Treatment for Minimal Residual Leukemia
スポンサーリンク
概要
- 論文の詳細を見る
M0-marrow is defined as a condition in which no apparent leukemia cell is seen in the bone marrow morphologically, cytogenetically or immunologically. However, M0-marrow may contain minimal residual leukemia (MRL) cells. Therefore, the treatment for MRL after complete remission is nessesary for curing the acute leukemia. Although it is not easy to evaluate the effect of treatment for MRL, the author conclude that the treatment would be effective if the prolongation of remission duration and the cure of the leukemia were achieved.After reviewing patients with acute leukemia in remission, the treatment for MRL is considered to be effective if it is done more intensively and as early as possible after complete remission. Following therapies are in progress in our department; intensive post induction treatment similar to induction chemotherapy or high dose ara-C for AML, and intensive chemotherapy with severely myelosuppressive drugs (ADR or DNR, ara-C, CY and pred) after LVP regimen for ALL.
- 一般社団法人 日本血液学会の論文
一般社団法人 日本血液学会 | 論文
- 健常者ならびに播種性血管内凝固(DIC)例における血漿アンチトロンビンIII (AT-III)の抗トロンビン活性と抗原性の比較
- 新生児の凝固・線溶阻止因子の動態
- All-trans retinoic acid投与中に広範な脳梗塞を生じた急性前骨髄球性白血病
- C/EBPβのショートアイソフォームであるLIPはマウス移植モデルにおいてEvi1と協調作用して急性骨髄性白血病を誘発する
- 成人に発症したビタミンK依存性血液凝固因子欠乏に関する臨床的解析